Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)Scott Kopetz, Howard S. Höchster, Luis A. Díaz et al.|Journal of Clinical Oncology|2020Cited by 391
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaperArvind Dasari, Scott Kopetz, Van K. Morris et al.|Nature Reviews Clinical Oncology|2020Cited by 365
Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancerZ.-Y. Chen, Scott Kopetz, Kanwal Raghav et al.|British Journal of Cancer|2015Cited by 148
Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC).Frank A. Sinicrope, Jeffrey A. Meyerhardt, Fang‐Shu Ou et al.|Journal of Clinical Oncology|2025Cited by 47
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trialAaron S. Mansfield, Keith T. Flaherty, Zihan Wei et al.|npj Precision Oncology|2022Cited by 42